scout
|Videos|August 17, 2017

Dr. Willmott on FDA Approval of Maintenance Olaparib in Ovarian Cancer

Lyndsay J. Willmott, MD, a gynecologic oncologist with Arizona Oncology, discusses the FDA approval of olaparib (Lynparza) in the maintenance setting for relapsed patients with platinum-sensitive ovarian cancer.

Lyndsay J. Willmott, MD, a gynecologic oncologist with Arizona Oncology, discusses the FDA approval of olaparib (Lynparza) in the maintenance setting for relapsed patients with platinum-sensitive ovarian cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME